Arvoni

Arvoni is a brand name that has been used for a fixed-dose antiviral medication intended to treat chronic hepatitis C virus (HCV) infection. The formulation combines ledipasvir and sofosbuvir, two direct-acting antivirals that target different steps in the HCV life cycle.

Mechanism and purpose: Ledipasvir is an NS5A inhibitor, while sofosbuvir is a nucleotide analog NS5B polymerase inhibitor. Together, they inhibit viral replication and help achieve sustained virologic response, which is considered equivalent to a cure for many patients with HCV.

Regulatory and branding status: Brand names for this drug combination have varied by country and over time. In some markets, Arvoni has been used alongside or replaced by other brand names such as Harvoni, or by generic formulations after patent expirations or licensing agreements. Availability and labeling can differ between regions.

Clinical use: The regimen is taken orally and is designed to be administered once daily. Duration is typically around 8 to 12 weeks or longer, depending on factors such as HCV genotype, prior treatment, and the presence of cirrhosis or other liver conditions. Treatment goals focus on achieving an SVR12, a measurable level of the virus that indicates a successful response to therapy.

Safety and interactions: Common adverse effects include fatigue, headache, and nausea. As with other DAAs, there can be important drug interactions, particularly with acid-reducing agents and certain concomitant medications. Patients should follow medical guidance and review all medicines with a healthcare provider.

See also: Sovaldi, Harvoni, Hepatitis C, direct-acting antivirals.